Merck (MRK) Completes Acquisition of Acceleron Pharma (XLRN) Nov 22, 2021 06:45AM
Merck Completes Acquisition of Acceleron Pharma Inc. Nov 22, 2021 06:45AM
Merck (MRK) Completes Tender Offer to Acquire Acceleron Pharma (XLRN) Nov 22, 2021 06:26AM
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. Nov 19, 2021 06:06PM
Merck (MRK) Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma (XLRN) Nov 17, 2021 06:46AM


Nov 17, 2021 06:45AM Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Nov 8, 2021 04:32PM Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and Austria
Nov 8, 2021 04:30PM Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
Oct 29, 2021 04:34PM Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Oct 12, 2021 06:51AM UPDATE: Merck (MRK) Commences Cash Tender Offer to Acquire Acceleron Pharma (XLRN) for $180/sh, Deal Announced on Sept. 30
Oct 12, 2021 06:45AM Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
Sep 30, 2021 06:46AM Merck (MRK) to Acquire Acceleron Pharma (XLRN) for $180 Per Share in $11.5 Billion Deal
Sep 30, 2021 06:45AM Merck to Acquire Acceleron Pharma Inc.
Jul 28, 2021 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
Jun 11, 2021 06:11AM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Present First Results from Phase 2 BEYOND Study of Reblozyl in Adults with NTD Beta Thalassemia
Jun 11, 2021 03:00AM Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Feb 16, 2021 07:38AM Bristol Myers Squibb Canada (BMY), Acceleron Pharma (XLRN) Announce Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
Feb 16, 2021 07:37AM Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
Sep 29, 2020 06:59AM Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
Jun 26, 2020 09:17AM Bristol-Myers Squibb (BMY) Announces EMA Approves Reblozyl for Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
Jun 26, 2020 09:05AM European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
Apr 30, 2020 05:13PM Bristol (BMY) and Acceleron (XLRN) Announce Reblozyl Receives Positive CHMP Opinion for Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 30, 2020 04:16PM Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 3, 2020 05:08PM U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS
Mar 26, 2020 07:01AM Bristol-Myers Squibb (BMY) and Acceleron (XLRN) Announces NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl in Adult Patients With Beta Thalassemia
Mar 26, 2020 06:59AM New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Jan 9, 2020 07:00AM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce NEJM Publishes Results of Pivotal Phase 3 Reblozyl MEDALIST Trial
Jan 9, 2020 06:59AM New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Dec 9, 2019 04:47PM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at ASH
Dec 9, 2019 04:30PM Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Dec 6, 2019 12:07PM Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announces FDA Will Not Review Reblozyl at ODAC Meeting
Dec 6, 2019 12:05PM Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Dec 3, 2019 07:39AM Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announce FDA Advisory Committee Will Review Reblozyl for Use in Patients With Myelodysplastic Syndromes
Dec 3, 2019 07:38AM Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
Nov 8, 2019 12:33PM FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
Jun 4, 2019 07:32AM Celgene (CELG), Acceleron Pharma (XLRN) Announce FDA Accepts Luspatercept BLA in Myelodysplastic Syndromes and Beta-Thalassemia
Jun 4, 2019 07:30AM Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
Apr 26, 2019 07:30AM Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Apr 5, 2019 09:28AM Celgene (CELG), Acceleron Pharma (XLRN) Announce Submission of Luspatercept BLA to U.S. FDA
Apr 5, 2019 09:28AM Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
Dec 3, 2018 05:56AM Celgene (CELG), Acceleron Pharma (XLRN) Report Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes
Dec 2, 2018 05:00PM Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Dec 1, 2018 05:00PM Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
May 1, 2017 09:13AM Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
Dec 7, 2015 05:02PM Celgene (CELG), Acceleron (XLRN) Announces Preliminary Results from Two Phase 2 Trials of Luspatercept in Beta-Thalassemia Presented at ASH
Dec 7, 2015 05:00PM Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Dec 5, 2015 12:30PM Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Ex
May 5, 2015 07:03AM Bayer CropScience and Flagship Ventures Form Strategic Innovation Partnership to Fund Leading-Edge Agriculture Ventures